Showing posts with label small cap stocks. Show all posts
Showing posts with label small cap stocks. Show all posts

Thursday, March 31, 2016

Richmont Mines Hangs In For Long Haul

I am impressed with Richmont Mines (US ticker RIC). Their longevity and profitability in 2015 were rare in a junior resource producer. The main challenge ahead is to replace mined reserves, either with new discoveries or with better engineering to make discovered resources viable.

The management team must be doing something correctly. Their mining engineer CEO has been around other producing companies. It's nice for once to see actual mine operators running a mining company instead handing the place over to former consultants or investment bankers. Their other key people have been around the block in the mining sector for a while.

The company has two active mines in Canada, plus other properties in various stages of exploration and development. The PEA for the Island Gold mine and the latest 43-101 for the Beaufor mine are on Richmont's website. My problem is that the PEA is abbreviated and the 43-101 is in French. Someone in charge over there needs to show me the long forms in my own language. I prefer to examine complete primary source documents in English. I am going to take the company's word that independent parties have verified its 2P reserves and ore grades.

Results in recent years aren't stellar compared to the larger world economy, but are probably better than countless mining companies facing bottomless financial holes during a bear market for metals. Profit margin at 4.72% (from Yahoo Finance today) isn't great, but plenty of resource sector investors would like to see that kind of money after holding other beaten-down mining stocks. Check out Richmont's numbers at Reuters. Its five-year EPS growth rate of -18.39% shows that even solid operations can't hold back a bear market in metal prices. Its five-year ROE and ROA are both below one percent, which are also below their industry averages.

Richmont Mines is somehow surviving when its larger competitors are struggling and the sector's juniors are cratering. Someone has to occupy the middle of the market.

Full disclosure: No position in Richmont Mines at this time.

Friday, January 15, 2016

Sunday, January 03, 2016

CytoSorbents Continues Despite Disappointing Financials

CytoSorbents Corporation (ticker CTSO) has a brand new approach to removing blood impurities in critically ill patients. Hemoperfusion is one of several extracorporeal methods that capture and remove potential threats from blood. IBISWorld thinks the total blood dialysis market is quite large, and the revenues of publicly traded dialysis leaders are indeed sizeable. A simple glance at the financials of dialysis market leaders Eli Lilly (ticker LLY), Baxter International (ticker BAX), and Fresenius Medical Care (ticker FMS) shows how difficult it will be for Cytosorbents to make headway.

The most relevant comparison should be between CytoSorbents and Fresenius because their product lines are both specific to the blood dialysis market. Here's a basic comparison, from the latest available reporting periods.

CTSO
Gross revenue (ttm): $3.9M
Profit margin: -284.9%
ROE: -127.6%
EPS: -$0.69

FMS
Gross revenue (ttm): $17.1B
Profit margin: 6.12%
ROE: 12.2%
EPS: $1.72

It's not even close. Fresenius is by far the more successful company. I'm not sure why CytoSorbents even went public in the first place, or why their executive team's compensation is so high, given their very poor financial performance. They have almost doubled their gross revenue each year since 2012 but their negative net income grows even larger. That's just plain embarrassing.

I had some hope that a deeper look into CytoSorbents would reveal something worth seeing. I just can't see past those very disappointing top line and bottom line results over several years. The retained earnings were over -$130M by the end of September 2015, and that's a huge negative hole for a small company fighting into a mature market with high regulatory barriers. I don't think I need to take this any farther. It is obvious that CTSO does not deserve to be anywhere near my own money.

Full disclosure: No position in CTSO or any other stocks mentioned at this time.

Monday, December 28, 2015

BioPharmX Losing Even More Money in 2015

BioPharmX (ticker BPMX) is another small pharmaceutical company with big plans to shake up drug delivery in dermatology and women's health. Plans are one thing, operations are another. Talented management teams are supposed to translate strategic plans into operational success.

The company's management backgrounds make me wonder whether the right people are in the right positions. The current CEO and president both have very diverse backgrounds helping other tech-related companies, but growing a young drug company demands years of drug-specific focus. Their SVP for marketing has worked in plenty of sectors except drugs. I am used to seeing such oddly diverse backgrounds in small-cap mining companies that have trouble developing a viable project, but it is disappointing to see such a mix in a drug company.

Their primary products, according to the company's website, are a topical antibiotic for acne and an iodine tablet for treating fibrocystic breast condition. Knowing the market opportunity should matter for investors. IBISWorld's market research report from February 2015 puts the size of the acne treatment market at $644M, with up to 50M Americans afflicted. GMR Data puts the market size higher at $3.1B for the same population. Divide the market size by the number of patients to get an average annual spend per person. MPR lists the leading anti-acne formulations and their doses. The many treatments available make for a saturated market. Fibrocystic breast condition is a mildly discomforting condition, according to searches with WebMD and the Mayo Clinic. The condition is so inconsequential it typically doesn't even require treatment unless a cyst becomes a marker for cancer.

BioPharmX's BPX01 anti-acne treatment is still in its clinical stage, so it's impossible to know its retail price point in a market crowded with generics. The company's BPX03 for breast pain must compete directly with very cheap OTC pain relievers. New drugs treating common symptoms already covered by cheap treatments are usually redundant unless they offer massive improvements.

Read the 10-Q dated December 15, 2015. BioPharmX had US$2.2M in cash on hand on October 31 and a net loss of -$11M for the prior nine months. The company must raise significant new capital frequently just to survive with that kind of burn rate, so investors can expect continued dilution. The stock market reacted to the company's December 14 "breakthrough" announcement, and then drove the share price back down in the weeks since then. The press release describing the BPX01 research results doesn't reveal much useful information.

BioPharmX had a very unprofitable 2015 even after ramping up SGA expenses. They also lost money in the prior two years. A drug company whose ability to deliver a quality product is largely unknown must rely on some compelling "story" of unmet market needs and past management successes. The BioPharmX story needs a better second chapter.

Full disclosure: No position in BPMX at this time.

Sunday, December 27, 2015

Figuring Out Aoxing Pharmaceutical's Future

Aoxing Pharmaceutical (ticker AXN) is one of those Chinese drug companies that wanted a US stock market listing. Such listings are a smart move if a thriving foreign company wants to raise capital here or expand operations beyond its home country. Either option will now face an uphill climb after some December news items about the company.

The company's CFO announced his resignation on December 4, 2015. That is not always a bad sign for a company aiming for a new growth phase, but consider some context. The resignation follows a report on December 2 that Pommerantz LLP is investigating alleged claims of Securities Exchange Act violations, and a December 3 report that Bronstein, Gewirtz & Grossman is also investigating Aoxing. It's hard to tell whether the allegations are substantial or simply a routine investor argument with management. Growing companies can experience these events in isolation, but investigations preceding a key resignation are a concern. Investors deserve an explanation but the company's web page reveals no news releases as of today responding to the law firms' allegations.

At first glance, Aoxing's profit margin of 22.83% and operating margin of 35.8% should indicate health. These measures don't square with the company's five-year average ROA of -18.68% and five-year average ROE of -50.75%. Aoxing's 2015 financial results show a sudden reversal of fortune after net losses in 2013 and 2014. Significantly higher gross revenue helped in 2015, in spite of persistently rising total liabilities and several negative changes in operating cash flows. Aoxing's SEC 10-Q filing dated November 13, 2015 notes in its MD+A how a shift in sales strategy from a third-party agent network to direct sales drove revenue growth. The strategy's reliance on independent direct sales will face challenges as China's drug distribution market changes.

Reviewing English-language reports on China's drug market reveals reasons to be concerned about any young Chinese drug company's ability to grow. AT Kearney's "China's Pharmaceutical Distribution: Poised for Change" reveals a fragmented distribution market and poor supply chain visibility. The US FDA's country director for China testified in 2014 about how hard US drug regulators are working to ensure Chinese drug exports meet US standards. Aoxing's future success in distribution will depend very much on securing healthy relationships with the three or four Chinese companies that will likely absorb much of the country's drug distribution network during consolidation.

Pharmaceutical companies with strong IP portfolios can tolerate high debt/equity leverage because their drug patents are supposed to be money makers. Aoxing's leverage will test US markets' tolerance if the company cannot sustain its net income improvement into 2016. The market is already showing its concern as the price of AXN fell from US$2.20 on June 8 to $0.92 on December 24. The company cannot blame this share price disappointment entirely on China's currency devaluation. Investors have a right to wonder how Aoxing responds to its US legal critics and China's changing drug distribution landscape.

Full disclosure: No position in AXN at this time.

Wednesday, March 18, 2015

Galectin Therapeutics (GALT) Misfired In 2014

Galectin Therapeutics (GALT) just cannot catch a break these days.  They announced a Q4 loss this week, just a day after a law firm announced an investigation of the management team's investor relations program.  It's fair to wonder what went wrong.

One of the company's drugs is GR-MD-02, a treatment for nonalcoholic steatohepatitis (NASH) with advanced fibrosis.  The possible reversibility of fibrosis tempts drug makers to develop treatments.  Alcoholics everywhere will rejoice when their liver problems are solved.  Non-alcoholics will be even happier with a solution for fatty buildups that inflame livers.  Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are related ailments.  The size of the market for fibrosis treatment can be approximated from CDC data on CKD and ESRD, and Medicare pays for a decent slice of the ESRD treatment market.  In other words, a fibrosis treatment would reap financial rewards.

Here's a run-down of Galectin's select metrics from Reuters.  The company's ROA, ROI, and ROE are all disastrous over both the short term and long term.  Galectin's destruction of investor capital is evident in over three years of progressively negative retained earnings.  The GR-MD-02 drug has been under development at least since 2009, according to research papers Galectin cites on its website.  More than half a decade is sufficient to show satisfactory Phase 2 trial results, and yet Galectin is just now beginning Phase 2 for GR-MD-02.  Efficiency is not this company's strong suit.

There is no turnaround in sight.  Galectin will spend more years burning cash until it gets test results, if ever.  I cannot be certain whether its drug pipeline will ever reach an addressable market for liver disease patients comparable to the CKD or ESRD markets.

Full disclosure:  No position in GALT at this time.

Tuesday, August 12, 2014

Viggle Needs Income to Make Its Share Price Jiggle

Viggle (VGGL) is one of those small online companies crying out for attention.  I'll be generous and give them some.  Their main properties are an entertainment rewards platform, a content sharing platform, and an audience analytics suite.  My Google searches of those terms reveal that none of Viggle's brands are on the first page of search results.  That must be discouraging for these folks.  Viggle's app partnership with DirecTV counts as a good user engagement method but I don't see what would prevent DirecTV from tweaking its own apps to capture Viggle's rewards traffic.

The Viggle team is extremely large for an app developer.  Consider that successful app companies in Silicon Valley have a handful of employees.  Their financial statements should indicate whether all of these people add value.  The 8-K dated June 25, 2014 reveals a merger with Choose Digital that cost Viggle almost 2M shares (a significant dilution) and created a contingent payment of almost $4.8M, payable in about a year.  That wouldn't be such a bad hole to crawl out of if Viggle had sufficient net earnings to pay it off.  Unfortunately, the 10-Q for May 14, 2014 shows Viggle is not profitable.  They had about $1.4M in cash on hand back in March but lost almost -$14M for that quarter.  That burn rate puts them at going concern risk on a weekly basis.  Check out their SGA of $18.8M; that's what that huge team displayed on their website costs.  Silicon Valley VCs get sticker shock when they fund a company that blows through its investment hiring unneeded people before their sales justify expansion.

Viggle is a good case study showing that user engagement stats and lots of app store downloads don't necessarily translate into revenue.  The history of this company as entities named Function (X) and Gateway Industries escapes me, but it's irrelevant.  This one really reminds me of Inuvo, another Web portal I evaluated today.  Only so many online rewards marketplaces will ultimately prove viable; the rest will end up selling to each other in a frenzy of blowout, self-cannibalizing referrals.  I've given Viggle more attention than it deserves.  It will get more attention if it cuts its burn rate and becomes profitable.

Full disclosure:  No position in VGGL at this time.

Saturday, January 18, 2014

Stellar Biotechnologies Makes KLH Applications

Stellar Biotechnologies (KLH.V / SBOTF) makes targeted therapeutics from keyhole limpet hemocyanin (KLH).  This protein is cultivated from mollusks called keyhole limpets in some kind of aquaculture.  The CEO is a scientist who invented the extraction method this company uses, and he formerly ran an aquaculture company.  I can't think of a more appropriate combination of scientific and business backgrounds.

I am impressed that a single source of protein enables multiple products in vaccine carriers and test kits.  Vaccine carriers typically have cold change storage requirements, so it will be interesting to know the shelf life of a KLH-based product.  I am further intrigued that this business model does not depend on the success of one specific vaccine because the basic protein can be adapted to the needs of multiple vaccines.

Stellar's success depends on executing licensing agreements rather than clinical trials.  I searched SEDAR for their financial statements because I didn't see anything useful in EDGAR.  Their annual statement for the year ending August 31, 2013 showed almost US$7.9M in cash on hand, and annual losses of almost -US14.9M.  They still have to raise significant amounts of money because their increasingly negative retained earnings shows them going farther in the hole every year since 2011.

I think their technology holds promise, but they need to execute some licenses.  Negligible revenue for a company that has been publicly traded for almost four years makes me wonder whether vaccine makers are getting Stellar's value proposition.  BTW, other companies (such as biosyn) also market KLH products.  Stellar must show the market some major clients to prove it has something worthwhile.

Full disclosure:  No position in Stellar Biotechnologies at this time.  

Friday, January 10, 2014

Pluristem Therapeutics Moving Somewhere

I had to check out Pluristem Therapeutics (PSTI) just to see what's going on in biotech.  I have to remind myself that other sectors exist besides the ones I usually review.  This one develops placental cell therapy solutions.  I don't know enough about biology to determine whether this technology works.  Their bioreactor process looks like it's scalable to large-volume production but I'm not sure how to assess the size of their potential market.

Their product must be competitive on a price per dose basis with other treatments (injection, radiation, oral doses, etc.) for inflamed tissues.  I evaluate progress in biotech companies when their announced milestones for successful trials and regulatory approvals move the share price.  Alternatively, a private company meeting these milestones will be able to successfully raise capital at higher valuations.  Let's review their press releases and compare them to the stock's movements over at Yahoo Finance.  Pluristem announced several clinical trial results in 2010 and yet the stock didn't move appreciably beyond a buck and a half.  The stock finally started to move up in early 2011, and that year they announced several iterations of positive data along with FDA orphan drug status.

This company started 2003 with a much higher valuation than they have today.  Such a steep decline in a decade makes me wonder who was so optimistic about them in 2003.  They did a shelf registration in January 2011 so maybe something really was different back then.  Whatever.  I don't have the patience to dig through decade-old financial statements.  They're still publicly traded but they experience persistent net losses since 2011.  That lack of performance is enough for me not to have Pluristem in my portfolio.

Full disclosure:  No position in PSTI at this time.  

Wednesday, December 11, 2013

Makism 3D (MDDD) Is Making . . . No Income

Andy Chambers (whose website I cannot locate) sent me a pump mailer about Makism 3D Corp. (MDDD) and its 3D printers.  Wanna see the fancy mailer before I throw it out?  Okay, here it is below.



Wow, look at all the pretty colors.  It's too bad this promoted company's performance isn't as pretty as all of those pictures.  Read their 10-Q dated November 14, 2013.  They started out offering performance management tech to cellular operators until they merged with Umicron of the UK.  Hey, "Umicron" sounds like the name of a Transformer robot.  This company sure transformed, but they have yet to transform their 3D printers into products that sell.  Their zero cash and negative working capital moved them to accept a SEPA, a.k.a. an equity credit line.  I don't like companies that get involved with those instruments because without very tight covenants in place a large investor can cram a share price down to zero and force an acquisition.

The management team has little obvious experience in small-run manufacturing.  Their Wideboy product isn't even available yet.  The company itself notes that the OTC Markets Group has placed a trading advisory on its ticker symbol.  They further note that they are still negotiating for components and plan to relocate.  So, to recap, they have no product, no components, and no revenue.

This stock has an average daily trading volume in the millions.  The information above is publicly available and yet the stock is heavily traded.  The human race is really funny that way.  The 3D printing revolution has barely begun to hit the mass market.  It's too bad Makism 3D is so far behind.

Full disclosure:  No position in MDDD, ever.  

Monday, December 02, 2013

Summary of Metals and Minerals Investment Conference San Francisco 2013

The Metals and Minerals Investment Conference that took place last week in San Francisco is the latest name for the Hard Assets Conference (and before that, the Gold Conference) that I've been attending for many years.  This is the one annual event on my very busy calendar that I cannot ever miss.


Things started off right with a morning workshop from Benjamin Cox of Oreninc.  I was very impressed with this company's due diligence methods at a previous Hard Assets Conference and I was eager to hear their updates.  I like analysis that combines fundamentals with money flows because that's how you find bargains in any market.  Oreninc applies the wisdom of picking entry points in depressed markets, just like Warren Buffett used to do.  It was interesting to hear Benjamin's prediction that junior mining companies may survive this bear market only to fail in the recovery when creditors demand repayment.  His approach to investing in juniors also resembles one of the Buffett PIPE strategies that combines a private offer for equity with warrants.  His view on the market for lithium deflated my theory that lithium producers are underestimating demand from IoT devices, mainly because the lithium and graphite requirements for wearables are so small.

The keynote from US Global Investors is always interesting at these shows.  The firm is impressed with the "Chindia" market but I'm staying away from that region due to China's and India's huge internal problems and potential for conflict.  I do not agree with that firm's thesis that contrarian plays abound in today's markets.  Some sectors in the US and Europe may have declined but that does not mean they are undervalued.  I also disagree with the firm's thesis that high-speed rail stations in China will be retail anchors for US brand names.  More China analysts need to use the Keqiang Index instead of China's self-reported GDP figures.  The audience loved the photo slideshow of Thailand's Prime Minister Yingluck Shinawatra leading our President through a diplomatic event with a come-hither look, followed by a photo of our stern-looking First Lady subtitled "COMPLIANCE."  Every corporate presentation should be that hilarious.

Leading lights in mining company research held their panel on economic trends.  These conference panels have been saying for years that the world's bond markets will reject Treasuries and that US hyperinflation is imminent.  I agree but none of us can time this cataclysm precisely, so it continues to roll in slow motion.  Rick Rule opined that the low attendance at this conference was a contrarian indicator for the metals sector.  I'd like to see investor capitulation too at some point so I can get back in after selling most of my GDX holdings near the top.  The panelists were aware that HFT hedge funds are manipulating markets by paying for advance notice of quotes in split seconds.  I wish people would calm down about short-term swings from manipulation and use them to uncover mispriced securities.  The current market bubble is more than just the effects of HFT manipulation and tax incentives for using debt in share buybacks.  The Fed's easy liquidity has incentivized banks to extend easy prime brokerage credit to hedge funds and private equity firms.  This is not a fun game to play and a lot of people are going to be hurt when the music stops.

Adrian Day Asset Management weighed the relative attractiveness of bullion versus mining shares.  I note with chagrin Adrian's observation that mining costs have risen dramatically while large discoveries are declining in number.  That's why a lot of junior miners are going to fail before any bull market in the resource sector returns.  Adrian thinks raising capital is not accretive if companies use it to overpay for acquisitions.  I say juniors shouldn't be acquiring at all because their business is to develop good deposits.  Measuring purely on P/B value, as Adrian does, to show that gold stocks are cheap risks ignoring the quality of a company's earnings and deposits.  I was lucky to score a free copy of Adrian's book Investing in Resources at one of the exhibitor booths.  Perhaps that's a contrarian indicator that my lucky streak in the resource sector is about to begin again.

Rick Rule's keynote was about the fun of preparing a portfolio for recovery.  He offered more confirmation that the mining sector is priced cheaply.  Stories of executives squandering the capital they raised during the hard asset bull market from 2009-10 are common.  Rick thinks the mining sector bifurcated this past June and that about 70% of the sector is worthless.  That's a lot of small stocks headed for zero.  No wonder the exhibitor floor is so small this year.  Rick is one of the few investment professionals who recognizes the natural human tendency of confirmation bias that ignores information contradicting strongly held beliefs.  That's why most people make many poor investment decisions.

Dr. Ron Paul was the featured keynoter.  It's telling that he didn't use the permanent honorific "Congressman" which our nation's laws and political tradition entitle him to claim.  He'd rather be a doctor in retirement.  That shows humility.  My very first impressions from the original Gold Conference years ago included the huge following for Ron Paul among the gold bug crowd.  Their enthusiasm for his views has not dimmed and he was by far the most well-attended speaker.  I staked out a front row seat.


Dr. Paul talked at length about how his study of Austrian School economic philosophy led him to the discovery that bad monetary policy is a threat to personal liberty.  He was as critical as ever of the Federal Reserve, the dollar's reserve status, and the US's interventionist foreign policy.  The Fed's QE reminds him of the Founding Fathers' hatred of counterfeiting.  Dr. Paul's tour-de-force anecdotes through the Fed's modern history are worth repeating.  He liked Paul Volcker but thought Alan Greenspan should add disclaimers to his old Ayn Rand writings, and Arthur Burns admitted to him that the Fed isn't really independent of the President's policies.  He lauded the Occupy movement's diagnosis of America's social inequality but dislikes their preference for wealth redistribution to solve it.


I do not agree with Dr. Paul's stance on non-intervention in Iran's nuclear weapons program.  Tehran has clearly stated its intent to develop and use nuclear weapons against its neighbors and it is not at all a Western-style republic.  Dr. Paul is very intelligent but he is not a geopolitical analyst.  His naive non-interventionist writings in the 1970s and '80s lead me to believe he would have let Fascism take over Europe.  I also think he's delusional if he believes that young people want more freedom.  I did a Google search of "millennials trust government" and found plenty of polling results showing that young people want more government intervention and regulation even though they have little trust in government!  I used to sympathize with libertarian philosophies until I learned more about how real humans behave.  People never know what they want and will trust anyone with a slick sales pitch.  That's why Millennials and other generational cohorts are ready to be led around by their noses.  I've got some more bad news for Dr. Paul.  The Constitution's preamble says "promote the general welfare" and Article One's "Necessary and Proper Clause" gives the federal government a tremendous amount of leeway.  The government's promotion of canals, railways, land grant colleges, and westward expansion made this country prosperous and immune from foreign domination.


The audience questions for Dr. Paul ranged from intelligent to nutty.  I wish I could find active links to the US Gold Commission from the early 1980s because Ron Paul served on it and one of his fellow former commissioners showed up to ask whether Fort Knox's gold deposit has been audited.  Dr. Paul thinks there is actual gold in the US Bullion Depository but its ownership status may be in question, which is why it needs an audit.  Some other dude asked whether smart meters could feed data to the NSA.  Hello?  What planet is he on?  Smart meters read machine data and the NSA monitors human-generated data.  Get a clue.  Oh yeah, local gadfly "Starchild" showed up to advocate common cause between the Tea Party and the Occupy movement.  Good luck with that one.  Dr. Paul totally lost me when he said liberals and conservatives should both support personal liberty and oppose wars.  That is just not going to happen but people like "Starchild" will take it as gospel.  I've read enough Leo Strauss and Carroll Quigley to know that the Anglo-West's hereditary ruling elite simply won't allow such a confluence of political forces.  One final supplicant asked Dr. Paul whether a Cyprus-style bank solution could happen here.  He avoided a straight answer but I don't think he's aware of the joint US-UK plan titled "Resolving Globally Active, Systemically Important, Financial Institutions."  Yes, it really can and will happen here.  It's too bad Dr. Paul will be a footnote in our country's history, maybe a notch below other forgotten advocates like William Jennings Bryan.  I tried to meet him after his keynote but he was pretty much constantly mobbed as he made his way across the expo floor to the Korelin Economic Report booth for an interview.  Even James Dines' booth babes followed him around.  This guy had no idea that he was in the presence of greatness that day, namely Yours Truly from Alfidi Capital.

The next panel on precious metals brought forth more sector analysts.  The theory that big banks can manipulate gold prices or that central banks can hold them down morphs a lot in the imagination of many commentators.  I'll believe that when I see smoking gun evidence that no one can debunk.  One of the better explanations of gold's behavior came when a panelist said it can drop in value during inflation even if the early onset of inflation is a blowout stage for metals.  I don't listen to commentators who use the word "consolidation" because that is a technical term with no statistical validity, but people at these conferences like to throw it around.  We can always count on Indian retail demand for gold to stay strong because Indians buy it for religious reasons and bury it in temples.  We all saw gold rise after the 2008 financial crisis but US investors tend to have a herd mentality and sell gold when it drops in price.  The bombshell of this panel came from none other than Oreninc's Benjamin Cox.  Ben revealed that hedge funds hold a big chunk of US gold and a future crisis will force institutions to sell gold just to meet margin calls.  This will force the price of gold down.  Inflation will then force it back up, at least initially.  Ben also noted that the supply of metals cannot possibly keep up with population growth and therefore cannot substitute for a fiat currency in a modern economy.  He is one of the few people watching this sector who understands history.  Others who say "there's enough gold for everyone" are clueless.

Jay Taylor's workshop on deflationary forces inside an inflationary monetary regime closed out my first day at this show.  I share Jay's disdain for CNBC's cheerleading of Keynesian cultists while government agencies worldwide churn out false economic statistics.  He cited FRED data on rising excess bank reserves (series EXCSRESNS on Excess Reserves of Depository Institutions).  I won't spoil Jay's report by repeating his citations of stats on declining consumer confidence, a lower money multiplier, lower M2 monetary velocity, and other deflationary drivers.  Read his writings yourself and check out Mike Hodges' Grandfather Economic Report for more depressing data.

The conference's first day of knowledge deserves my own special reflection.  IMHO the last few months of FOMC minutes make it clear that some Fedsters doubt QE, but the Fed isn't truly independent of executive branch policy.  The Fed will likely go along with accommodative QE if a deflationary market crash leads to a government policy response that forces hyperinflation.  The time lag between the asset crash and the hyperinflationary effects of the combined Federal Reserve / executive branch policy response matter very much.  The Fed's treatment of bank reserves also matters.  If the Fed raises reserve requirements for banks, but then charges banks to hold reserves at the Fed, banks will be immediately forced to seek income.  Banks may then immediately charge fees to their own depositors (a deflationary lever) or immediately make riskier loans ( a hyperinflationary lever, forcing up the money multiplier).  I'd like to see historical evidence for hyperinflation in the economy of the world's reserve currency.  I suspect deflation is more likely in a world reserve currency's home economy, up until the point that currency loses its world reserve status when foreigners refuse en masse to hold it.  The status of that reserve currency may very well be the tipping point between deflation and hyperinflation in the home economy.  Many things could open a path to hyperinflation in the US once the dollar loses its reserve status.  Foremost in my mind is the end of petrodollar recycling but there are other possible triggers.

The second day started off with Rick Rule's boot camp on private placements.  These PPs are typically restricted to accredited investors.  Rick considers the company's amount of SGA expenditures versus its project expenditures, its stated purpose for a capital raise, and the deal's terms.  The warrants in a PP deal are key because a portfolio of private placements with warrants minimizes the expected failure of most of the companies, much like a venture capital portfolio.  Some frequent investors do "warrant stripping" if they have huge volumes of deal flow.  Rick thinks that's lucrative with the right expertise.  He likes full warrants better than fractions and longer durations (past two years) better than short ones.  I think his praise for debt PPs is more valid in riskier juniors because the debtholders will end up owning the company in bankruptcy.  He likes the rewards of bridge/mezzanine financing that include fees, regular coupons that beat booking of accruals, and upside participation.  That upside sweetener can be in the form of warrants, a royalty that the issuer can buy back, or a note convertible to equity.  Rick warned against companies that raise insufficient capital to complete their exploration program; that sets up failure and indicates a management team that isn't serious about a project.  I disagree with Rick's stated preference for political risk over technical risk because I'm not convinced that the best deposits lie in unstable countries.

The morning keynote from Casey Research described the next big investment bubbles.  The dude displayed a Photoshop merge of Janet Yellen with Ben Bernanke, just to illustrate that Calamity Jane at the Fed will be no different from Helicopter Ben.  I have a hard time believing the keynote's thesis that central banks are suppressing the gold price.  Some of the data on gold supply is selective and the claim that central bank gold leasing constitutes "missing supply" is difficult to discover through Mosaic theory analysis.  An argument for a supply shortage makes no sense to me if the price of gold has dropped significantly from its all-time highs.  Citing numbers from the depository warehouse for the SPDR Gold Shares ETF (GLD) means little if GLD also holds futures contracts on gold.  I cannot buy the argument that JPMorgan acts as the Fed's agent for suppressing the gold price because . . . JPM sold its gold warehouse!  It makes no sense for a SIFI bank to depart a scheme that holds forth guaranteed profits unless of course such a scheme never really existed.  I think a lot of gold analysts are misreading the "eligible" line on COMEX reports of gold deliveries.  I also think analysts are misreading the CFTC rules for trading organizations and the CFTC Bank Participation Reports.

I need to take a time out just to respond to the conspiracy mongers in the gold sector.  I just can't believe all this stuff about gold price manipulation.  Physical delivery satisfies real demand.  There is no point in risking a margin call on a big futures position just to manipulate the price of gold if you still have to make good on a physical delivery.  Where is the motive, means, and opportunity for SIFIs to suppress the gold price on behalf of central banks?  Why would they suddenly sell their trading warehouses and switch to long positions if central banks still have gold leases outstanding?!  The central banks would have to cover those outstanding leases at higher prices and book huge balance sheet losses.  One of the alleged motives for banks to suppress gold is to keep interest rates down so they can keep borrowing at zero and buy treasuries for the easy carry trade.  If that's so, why suddenly switch to long gold positions if that would place banks' bond holdings at risk of paper losses?  Is the Fed lined up to buy back their Treasuries?  Come on, people.  Conspiracy theories are less compelling than supply/demand fundamentals.

Everbank gave their traditional rundown of the global markets and the implications for currencies.  The PIIGS are obviously still sovereign debt risks and the poorer countries of southern Europe want to continue to borrow at Germany's preferential interest rates indefinitely.  That's my take, anyway.  It boggles my mind that homebuyers and college students are the only real loan demand sources in the US economy right now and the suckers are still lining up.  I've blogged before about how marginal increases in debt no longer drive comparable GDP growth and Everbank has noticed the same trend.  I will lay out Everbank's stated currency valuation factors:  GDP growth, high current account balance, low government budget as % of GDP, low debt as % of GDP, high real interest rates.  Gee, it looks like the US dollar fails on all counts.  Everbank likes the Swedish krona, Chinese renminbi, Brazilian real, and Mexican peso.  I don't like any of those currencies.  I have no need to keep money at Everbank.

The panel on exploration trends featured two speakers I recognized from my first ever stint as a panelist two years ago.  The TSX Venture Exchange is the best proxy for the exploration sector.  One panelist opined that year-end tax loss selling and fund redemptions will further depress shares in the exploration sector.  Hmmm, that means I'll wait until January to buy anything I'm watching now.  The panel's conventional wisdom is that prospect generator models are candidates for longevity but I've always viewed them as black holes for invested capital.  I'd like someone to name one great producing project that came out of a generator and made it to either stand-alone viability or acquisition by a major producer.  The panel thinks survivors have lots of working capital and royalty interests.  Well, I've looked at lots of balance sheets and NI 43-101 reports this year and those two things rarely go together.  They noted that resource nationalism is rising.  That's why I like the US, Canada, Australia, and New Zealand for their Anglo-Saxon common law traditions.  My worst picks for resource nationalism risk are Venezuela and Argentina for their collectivist responses to stagflation.  I'll also throw in North Korea as the worst place to invest because they kidnap and kill investors there.  The DPRK has untapped high-grade deposits of tungsten and rare earths, if drill samples from Chinese companies have credibility.  The panel did reveal some good red flags to watch in a troubled company.  The biggest warning is flow-through funding that progressively dilutes shareholders in subsequent rounds, which indicates rising risk of the company's projects.  They also noted red flags in environmental issues and fatal accidents.

A bunch of exploration company CEOs held a panel on making the grade in an investment strategy.  They claimed that owning large districts increases the chance of a big discovery but IMHO competent geologists can reduce exploration to a focused area.  They did reveal that different jurisdictions require different cutoff grades to be economically worthwhile.  They liked Visual Capitalist and I think its infographics follow the trend in Big Data towards convenient representations.

CPM Group gave its gold market outlook.  I was grateful for this data-driven analysis as an antidote to conspiracy theories about gold.  I did learn that the premia on US Mint coins is a proxy for investor demand for gold.  The COMEX Gold Futures and Options weekly data on net fund positions indicate changes in demand for gold, as do changes in gold ETF holdings.  Many things affect gold supply.  Look at annual production and new gold mine capacity for indications of changes.  This sharp guy noted that gold and inflation are unlikely to surge while the US and other developed economies have high unemployment and excess manufacturing capacity.  I take that to mean that gold's best days are ahead, maybe, at some point.  Any Fed tapering that raises real interest rates would cause the gold price to drop.

I'll say one thing about something I heard from another self-styled gold expert at this show.  I'm tired of hearing stories about how some stock that trades for less than the cash on its balance sheet is some kind of screaming buy.  I consider that cash to be a depleting asset that is supposed to be used in a productive exploration program.  It will go to zero if it funds a drill program that doesn't work.

I liked Dudley Baker's talk on his Common Stock Warrants platform.  The site looks good and Dudley advised us to perform leverage calculations on warrants to determine their likely ROI.  He also thinks warrants are useful in combination with traditional stock options.  I'd like to see someone run a platform that makes contingent value rights (CVRs) just as transparent and easy to use in combination with other instruments.

The conference concluded with the traditional bulls and bears debate among Rick Rule, Jim Dines, Adrian Day, Al Korelin, and Jay Taylor.  The lineup changes a little each year but it's always lively.  They couldn't reach a consensus on whether the junior resource sector has bottomed but Jim sure likes the 3D printing sector.  The question of whether there's really gold at Fort Knox was in keeping with the "audit the Fed, audit Fort Knox" meme that's symbolic of a general distrust in government.  Jim thinks the gold has been audited but that Americans just don't care.  I would really like to know whether foreign intelligence services are feeding this auditing debate by seeding "information operations" elements among the libertarian fringe.  Rick asked his panelists about their most important lesson from the junior mining sector's downturn.  Well, now it gets interesting.  Jim told a bizarre story about the Clintons that made no sense.  Al wants us to stay diversified, just as I recall him saying many times over the years of this conference.  Want my most important lesson?  Here it is.  I learned that there's more to hard assets than gold bullion and gold stocks!  A basket of hard assets includes precious metals, base metals, energy, timber, REITs, and sectors like pipelines and railroads that service them all.  Jim also snapped out of his daydream about the Clintons to remark that the low attendance at this conference indicates a low for the sector's valuation.  Rick had a special zinger question just for Jim about what was interesting in the many conversations at his booth.  Jim said he noticed fear among his attendees, another market bottom anecdote.  He wandered off into his geopolitical theories but I was left reminded of Warren Buffett's advice to be greedy when others are fearful.

I noticed the low attendance too.  I've been at this conference series through all of its name changes since 2005.  The decline in attendance and exhibitors has been noticeable.  This was the first time since then that all of the exhibitors and workshops fit on the same floor of the SF Marriott Marquis and the expo floor only took up about half of the available concourse space.  Several paid exhibitors didn't even show up at their booths, namely Equities.com, Mining Leaders, and the Financial Survival Network.  I know darn well how expensive those booths are because I manned one myself in 2006.  The depressed junior mining sector isn't the only thing hurting attendance.  Investor relations promoters are now able to hold webinars and virtual roadshows over social media broadcast tools.  Traveling to a trade show is hard for people who can get the same content over the Web.  I like this particular show and I will attend for as long as it exists, regardless of how many times they change their name.  I'm all about booth babes, free knowledge, and hard assets.

Thursday, November 28, 2013

Sovereign Lithium (SLCO) Makes Me Scratch My Head

I got a random freebie mailer from some "economic advice" newsletter promoting Sovereign Lithium (SLCO).  I generally don't read newsletter publishers who claim to give advice because that is the proper function of financial advisers who hold NASD securities licenses.  I searched FINRA BrokerCheck for the newsletter's publisher and did not find a listing for his name.  Anyway, this article should be about the stock and not the PR.

Sovereign Lithium's management team has broad experience in corporate transactions but only one person listed at present has obvious experience specific to lithium production.  They have an option to acquire ownership of the Big Smoky Valley lithium property.  That's it, folks.  There's very little in the information they have posted that makes me think they have a solid plan to mine the site if they can raise the capital to buy it.

Read the 10-Q from October 25, 2013.  This company used to be called Great American Energy, and before that it was Southern Bella.  I have no idea what the previous entities' involvement in catering and entertainment has to do with lithium mining in Nevada.  Note the option to explore a property in British Columbia for rare earth elements.  I have no idea what that has to do with lithium either.  Note the admission of going concern doubts.

Here's the part where I sigh and scratch my head.  The SEC suspended trading in SLCO on November 19, 2013.  Sovereign Lithium issued a statement on the matter, and said statement is included in that 8-K dated November 19.  I'm not interested enough in this company to stick around for the opening bell when trading resumes in SLCO.

Full disclosure:  No position in SLCO, ever.  I am not a financial adviser.  I do not give financial advice to investors.  

Sunday, September 01, 2013

API Technologies Corporation (ATNY) Not For Me

API Technologies Corporation (ATNY) offers a complex line of electronic components and systems to government customers in the NATO countries.  The business model is right up my alley but defense contractors everywhere are up against major economic headwinds.  Many European NATO countries will have to trim spending to stay within EU budget guidelines.

They've been losing money for the past three years, with only the most recent quarter showing positive earnings.  Their long term debt has absolutely exploded since 2012.  Their retained earnings are massively negative and FCF for much of their recent history has been negative.

I'm sorry, folks, but if the financials don't meet my standards then I don't waste time delving into the business model.

Full disclosure:  No position in ATNY at this time.  

Wednesday, August 14, 2013

Alfidi Capital Slides For MoneyShow SF 2013 Seminar

I have published the PowerPoint slides I will use tomorrow during my seminar at the MoneyShow San Francisco 2013.  The slides and notes are available at the Alfidi Capital main site in the Special Reports section.  I will focus on small cap stocks in the natural resource sector with mining stocks as my primary examples.

They gave me 30 minutes for my seminar.  I plan to talk for at least half that time and leave time for questions.  I don't like being interrupted when I give talks but some people will probably do it anyway.  I will try my very best to be polite.  I expect my attendees to behave the same way out of courtesy for everyone.

I want my audience to admire my extreme genius and leave inspired to be better human beings.  I do not want any troublemakers.  I will be more than happy to call venue security and law enforcement to handle anyone who is disruptive.  My enemies need to stay home tomorrow.

My sacred mission in life is to display my genius in public and that is why I am speaking at the MoneyShow.  I will be available afterwards for congratulations and for photos with attractive women.  Ladies, wear your best attire to get my attention and have your phone numbers ready.  

Friday, July 12, 2013

Anthony Alfidi Seminar at MoneyShow San Francisco 2013

If you people haven't filled your August calendars with action, I've got something for you to do.  I'm presenting a FREE seminar on investing in small-cap stocks at the MoneyShow San Francisco, one of the world's most popular investment conferences.  Register to attend the conference for FREE and you might learn something about how I evaluate stocks for inclusion in my portfolio.  There's more to the MoneyShow than just me.  The entire conference is jam-packed with insights into products, theories, and asset classes.  

Regular readers of my blog know the basics of my approach to small-cap stocks.  I follow the natural resource sector closely and look for stocks with appropriate management, verifiable estimates of deposit quality, and enough capital to meet their intended milestones.  I will elaborate on the mechanics of this methodology live and in person.  

I must also warn any potential troublemakers that the conference organizers and hotel staff take a very professional approach to maintaining decorum.  My controversial writing has resulted in threats of harm to my person over the years.  I ignore these threats because stupid people deserve to be ignored.  I am more than prepared to defend myself but that is less important than the safety and comfort of fellow conference guests.  I want all of my seminar attendees to feel safe in a disruption-free environment.  Conference and hotel staff will remove anyone who attempts to disrupt my seminar.  I will fully support law enforcement in any judicial action against someone who causes trouble in my seminar.  

Come to my MoneyShow seminar to learn.  Stay away if you only cause problems.  Oh BTW, I will be available after the conference for extended discussions, especially with attractive women.  

Sunday, July 07, 2013

Tonix Pharmaceuticals (TNXP) Fighting Fibro

Tonix Pharmaceuticals (TNXP) thinks it has a drug that can treat fibromyalgia.  TNX-102 is an oral tablet that delivers cyclobenzaprine.  NIH's page on cyclobenzeprine notes that its commercial names are Amrix and Flexeril, both prescribed short-term to treat muscle spams.  The regulatory pathway through the FDA's "pain division" is known thanks to work by competitors.  FDA approval for chronic therapy in fibro patients means longer exposures to possible side effects.

The most impressive factor in this company's story right now is the background of their management team.  Dr. Seth Lederman has extensive experience in immunology and pharmaceuticals.  Other key people on the team have decades of experience with leading drug developers.

The market for fibro drug treatment is quite large.  Decision Resources estimates the fibro pain management drug market will grow to US$1.8B in 2018, with the caveat that the entry of a generic version of pregabalin (brand name Lyrica from Pfizer) will drop that figure to US$1.4B immediately thereafter.  Tonix's real competition for TNX-102, assuming it passes all FDA hurdles, is therefore a low-priced generic.  Pfizer has been milking Lyrica for all it is worth after winning patent exclusivity in 2012, and will continue to do so especially if it can treat epilepsy.

Tonix does have other drugs in its development pipeline.  Investors should watch the company's news releases for progress with its FDA studies.  It would be relevant to know whether TNX-102 is more effective at suppressing fibro symptoms than pregabalin, with fewer side effects, at lower costs.  Two out of those three would give it a marketable case against a generic.

Full disclosure:  No position in TNXP or other companies mentioned at this time.  

Thursday, July 04, 2013

Asanko Gold Used To Be Keegan Resources

Keegan Resources is now Asanko Gold.  Name changes do not change the underlying fundamentals of a company.  Asanko Gold used to trade as KGN.TO but now trades as AKG.  It's still a gold explorer in Ghana, an African country that ranks 64th on Transparency International's Corruption Index (above the median) and 77th in the Heritage Foundation's Index of Economic Freedom (above the median).  Ghana also ranks 108th on the World Bank's 2012 Logistics Performance Index.  Noting country risk is always important when evaluating investments in emerging markets.  Ghana is less corrupt and more stable than its peers but its infrastructure is still immature.

I had noted in my analysis of Cayden Resources last year that some of that company's management team also had responsibilities with Keegan.  That is no longer the case with Asanko's present management.  The Asanko team looks like they have a lot of experience with a variety of mining projects plus experience specific to Ghana.

The last time I checked on these folks when they were called Keegan, their Esaase project had MII resources.  They now have a 43-101 pre-feasibility study dated June 2013 that shows 2P reserves of 1.41 g/t Au.  That's not bad at all these days.  Good work, folks.  The PFS estimate for initial capex is US$286.5M with a total cash cost of production (I always ignore tax adjustments) of almost US$813/oz Au.

I like that their IRR estimated ranges at different market prices for gold have been fairly consistent at various stages of the Esaase project's development.  Yes, I've been tracking them for some time and I kept their previous estimates for comparison.  I'm concerned that the cash cost of production is significantly higher than gold's long-term average market price of US$615/oz.  Gold prices will have to remain significantly higher for the ten-year life of this mine for it to maintain its projected production.

Asanko's most recent quarterly statement dated March 31, 2013 shows cash on hand of about US$197M.  That is a phenomenal war chest but they will still need to raise more money to start production at Esaase.  The good news is that they seem to manage their burn rate quite well, which increases their chance of surviving until they can find a larger partner to help fund full production.

I like Asanko but I'm not buying the stock just yet.  I want to see whether a major producer finds the Esaase project attractive enough to make Asanko an offer they can't refuse.

Full disclosure:  No position in Asanko Gold at this time.  

Friday, June 14, 2013

Wednesday, June 12, 2013

Petrosonic Energy (PSON) Brings Something Sonic to Oil

Here we go.  Tobin Smith's Next Big Thing Investor mailed me a full-color teaser promoting Petrosonic Energy (PSON).  This stock has one of the more original business models of any small-cap I've seen in a mass mailer.  Most de-asphalting technologies in crude oil refining use solvents.  Petrosonic uses - as their corporate name implies - sonic energy.  They're certainly adventurous in locating their pilot project in Albania, which has a lot of heavy crude oil to process from its on-shore fields.  For the record, I've never dated Albanian women.

The CEO has experience as an oil executive but I'm concerned about whether the rest of the team has experience in petroleum engineering.  It's not obvious from their bios as presently written.  Refining oil isn't something just any manager knows how to do.  I have no idea whether their technology actually works, so we'll have to wait for data from their downstream refinery.  Do the Petrosonic people speak the Albanian language?  Do their local partners speak English?  That would be pretty important to know if they're going to understand the results of this particular engineering process.  Albania ranks 113 out of 176 in Transparency International's 2013 corruption index.  That's very important to know for anyone who wants to do business there.

Their 10-Q for May 30, 2013 admits to going concern doubts, and they will have to continue raising capital.  They did something clever by paying for investor relations and legal services with stock that can be repurchased.  It's nice that they're willing to conserve cash that way.  I'd be even more impressed if their technology really works.  They ended their most recent quarter with almost $2.2M cash on hand and a net loss of $765K.  That means they can last the rest of 2013 before another capital raise dilutes shareholders.  Oh BTW, they used to be called Bearing Mineral Exploration.  Whatever.

Petrosonic Energy is a risky play that doesn't fit my portfolio at this time.  Let's see if they can deliver scientifically verifiable results from their test project.  Tobin Smith can tell us all how it's doing if he takes a trip down to Albania.

Full disclosure:  No position in PSON.  

Monday, April 22, 2013

Lot78 (LOTE) Losing Money on Expensive, Trendy Threads

The pumpers at Trinity Investment Research never let me down when I need grist for my mill.  They sent me a cute mailer touting Lot78 (LOTE), some London-based luxury clothing seller.  I really couldn't care less about trendy clothing.  I wear cheap, boring threads until they fall apart.  Hot clothing retailers don't get me excited because the brain-dead consumers who sustain them with credit card purchases will soon be up against a financial brick wall.  I have digressed.  I must discuss this stock.

Their founder and CEO has a history in high-end clothing design.  That's nice but I can't understand why a brand that has successfully placed its lines in high-end retail chains is still losing millions of dollars per year.  Their retained earnings deficit gets worse every year and they have never generated any revenue.  Their annual report from April 5, 2013 shows that their auditor has going concern doubts and that they must raise additional capital to survive.  They admit they're in serious jeopardy of running out of cash.

What's most jarring about this company isn't the financial results, but its image.  The models wearing the clothes displayed on the website look bored or irritated, as if they're uncomfortable wearing the clothes.  Contrast this with the ads from dominant U.S. retailers like Macy's, where the models are overjoyed to be pictured in their clothes.  The Lot78 clothes themselves look drab with odd placements for exterior pockets and zippers.  I get the impression that some high-end clothing lines have signature styles that say "look at me, I'm expensive."  The message I would get if I saw someone wearing this stuff is more like "look at me, I'm stupid."  

I had to convert the item prices listed on Lot78's site from British pounds to US$ to figure out how much a San Franciscan in Union Square's shops would be set back.  Today's USD/GBP is $1 / 0.65 pounds.  Trans-Atlantic pop musicians and movie stars will always "need" $85 T-shirts and $306 lounge pants but commoners on both sides of the pond are bound to get hit with another financial crisis.  Broke urbanites will do without new clothes if every spare penny must pay the rent.  I don't understand why trendies spend money on spring and summer clothes that look as drab as a basement closet, and at premium prices.  I just don't understand retail at all.  That's why I don't own this stock or anything like it.

Full disclosure:  No position in LOTE at this time.